De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Nevro Beheer

Beheer criteriumcontroles 1/4

De CEO Nevro's is Kevin Thornal, benoemd in Apr2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.45M, bestaande uit 4.5% salaris en 95.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.07% van de aandelen van het bedrijf, ter waarde $ 146.54K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 5.2 jaar.

Belangrijke informatie

Kevin Thornal

Algemeen directeur

US$11.5m

Totale compensatie

Percentage CEO-salaris	4.5%
Dienstverband CEO	1.5yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

Analyse CEO-vergoeding

Hoe is Kevin Thornal's beloning veranderd ten opzichte van Nevro's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$77m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$11m	US$516k	-US$92m

Compensatie versus markt: De totale vergoeding ($USD 11.45M ) Kevin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Kevin te vergelijken met de prestaties van het bedrijf.

CEO

Kevin Thornal (50 yo)

1.5yrs

Tenure

US$11,453,548

Compensatie

Mr. Kevin R. Thornal serves as President & Chief Executive Officer at Nevro Corp. since April 24, 2023 and serves as its Director since May 2023. He joined Nevro Corp. on April 24, 2023. He serves as Acti...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Thornal	President	1.5yrs	US$11.45m	0.070% $ 130.3k
Roderick MacLeod	Senior VP & CFO	4.3yrs	US$2.58m	0.066% $ 123.1k
Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	6.8yrs	US$2.55m	0.13% $ 241.4k
Greg Siller	Senior VP & Chief Commercial Officer	1.3yrs	US$3.56m	0.058% $ 108.4k
Christofer Christoforou	Senior VP & COO	less than a year	US$2.87m	0.078% $ 144.0k
Angeline McCabe	Vice President of Investor Relations & Corporate Communications	less than a year	geen gegevens	geen gegevens
Shana Ross	Senior VP & Chief Human Resources Officer	1.8yrs	geen gegevens	geen gegevens
David Caraway	Senior VP & Chief Medical Officer	10.5yrs	geen gegevens	geen gegevens
Peter Socarras	VP, General Counsel & Corporate Secretary	no data	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVRO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Thornal	President	1.4yrs	US$11.45m	0.070% $ 130.3k
Susan Siegel	Independent Director	3.8yrs	US$242.99k	0.034% $ 63.6k
Shawn McCormick	Independent Director	10.1yrs	US$246.99k	0.072% $ 133.5k
Elizabeth Weatherman	Independent Director	5.6yrs	US$259.24k	0.17% $ 306.5k
D. Grossman	Non-Executive Chairman of the Board	5.6yrs	US$1.48m	0.52% $ 972.7k
Michael DeMane	Independent Lead Director	13.6yrs	US$284.99k	1.28% $ 2.4m
Kevin O'Boyle	Independent Director	5.6yrs	US$259.99k	0.065% $ 120.4k
Kirt Karros	Independent Director	less than a year	geen gegevens	geen gegevens
Karen Prange	Independent Director	4.8yrs	US$252.99k	0.040% $ 73.5k
Sridhar Kosaraju	Independent Director	3yrs	US$242.99k	0.062% $ 115.2k

5.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVRO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Nevro Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Nevro Corp., Annual General Meeting, May 23, 2024

Independent Director recently bought US$172k worth of stock

Nevro Corp. Announces Executive Changes

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Nevro Corp. Announces Executive Changes

General Counsel recently bought US$100k worth of stock

Recent updates

Consensus EPS estimates fall by 21%

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Consensus forecasts updated